Pathological characterization of T2*-weighted MRI contrast in the striatum of Huntington’s disease patients

Pathological characterization of T2*-weighted MRI contrast in the striatum of Huntington’s disease patients

Previous MRI studies consistently reported iron accumulation within the striatum of patients with Huntington’s disease (HD). However, the pattern and origin of iron accumulation is poorly understood. This study aimed to characterize the histopathological correlates of iron-sensitive ex vivo MRI cont...

Full description

Bibliographic Details
Main Authors:	Marjolein Bulk, Ingrid Hegeman-Kleinn, Boyd Kenkhuis, Ernst Suidgeest, Willeke van Roon-Mom, Jan Lewerenz, Sjoerd van Duinen, Itamar Ronen, Louise van der Weerd
Format:	Article
Language:	English
Published:	Elsevier 2020-01-01
Series:	NeuroImage: Clinical
Subjects:	MRI Iron Huntington’s disease Microglia Astrocytes Striatum
Online Access:	http://www.sciencedirect.com/science/article/pii/S2213158220303351

Similar Items

Étude de l'implication potentielle des marqueurs du striatum dans la maladie de Huntington
by: Galvan, Laurie
Published: (2011)

Possible involvement of self-defense mechanisms in the preferential vulnerability of the striatum in Huntington’s disease
by: Laetitia eFrancelle, et al.
Published: (2014-09-01)

Role du striatum dans la perception temporelle via un modele rat transgenique de la maladie de huntington
by: Hohn, Sophie
Published: (2011)

Connectivity-based segmentation of the striatum in Huntington's disease: Vulnerability of motor pathways
by: India Bohanna, et al.
Published: (2011-06-01)

Dysregulation of coordinated neuronal firing patterns in striatum of freely behaving transgenic rats that model Huntington's disease
by: Benjamin R. Miller, et al.
Published: (2010-01-01)

Proteostasis in striatal cells and selective neurodegeneration in Huntington’s disease
by: Julia eMargulis, et al.
Published: (2014-08-01)

Major Contribution of Somatostatin-Expressing Interneurons and Cannabinoid Receptors to Increased GABA Synaptic Activity in the Striatum of Huntington’s Disease Mice
by: Sandra M. Holley, et al.
Published: (2019-05-01)

Reconstitution du réseau corticostriatal et cible thérapeutique dans la maladie de Huntington
by: Virlogeux, Amandine
Published: (2018)

Early and brain region-specific decrease of de novo cholesterol biosynthesis in Huntington's disease: A cross-validation study in Q175 knock-in mice
by: Mahalakshmi Shankaran, et al.
Published: (2017-02-01)

Blocking Notch-Signaling Increases Neurogenesis in the Striatum After Stroke
by: Giuseppe Santopolo, et al.
Published: (2020-07-01)

The Role of Microglia and Astrocytes in Huntington’s Disease
by: Thulani H. Palpagama, et al.
Published: (2019-10-01)

The MID1 Protein: A Promising Therapeutic Target in Huntington’s Disease
by: Annika Heinz, et al.
Published: (2021-10-01)

BACHD Mice Recapitulate the Striatal Parvalbuminergic Interneuron Loss Found in Huntington’s Disease
by: Vyshnavi Rallapalle, et al.
Published: (2021-05-01)

Functional changes in neocortical activity in Huntington's Disease model mice: an in vivo intracellular study.
by: Edward A Stern
Published: (2011-06-01)

Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease
by: Carmela Giampà, et al.
Published: (2009-06-01)

CREB is a key regulator of striatal vulnerability in chemical and genetic models of Huntington's disease
by: Yun-Sik Choi, et al.
Published: (2009-11-01)

Astrocyte transduction is required for rescue of behavioral phenotypes in the YAC128 mouse model with AAV-RNAi mediated HTT lowering therapeutics
by: Lisa M. Stanek, et al.
Published: (2019-09-01)

Striatum and language processing: Where do we stand?
by: Bachoud-Lévi, A.-C, et al.
Published: (2021)

Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease
by: Alessandro Leuti, et al.
Published: (2013-04-01)

Intergenerational and striatal CAG repeat instability in Huntington's disease knock-in mice involve different DNA repair genes
by: Ella Dragileva, et al.
Published: (2009-01-01)

Selective striatal neuron loss and alterations in behavior correlate with impaired striatal function in Huntington's disease transgenic rats
by: Orsolya Kántor, et al.
Published: (2006-06-01)

Deficits in coordinated neuronal activity and network topology are striatal hallmarks in Huntington’s disease
by: S. Fernández-García, et al.
Published: (2020-05-01)

Reactive Neuroblastosis in Huntington’s Disease: A Putative Therapeutic Target for Striatal Regeneration in the Adult Brain
by: Mahesh Kandasamy, et al.
Published: (2018-03-01)

Evidence for Dysfunction of the Nigrostriatal Pathway in the R6/1 Line of Transgenic Huntington's Disease Mice
by: Å. Petersén, et al.
Published: (2002-10-01)

Region-specific astrogliosis: differential vessel formation contributes to different patterns of astrogliosis in the cortex and striatum
by: Haijie Yang, et al.
Published: (2020-07-01)

Resolving pathobiological mechanisms relating to Huntington disease: Gait, balance, and involuntary movements in mice with targeted ablation of striatal D1 dopamine receptor cells
by: Hyun Ah. Kim, et al.
Published: (2014-02-01)

Alterations of striatal indirect pathway neurons precede motor deficits in two mouse models of Huntington's disease
by: Irene Sebastianutto, et al.
Published: (2017-09-01)

Enhanced Ca2+-dependent glutamate release from astrocytes of the BACHD Huntington's disease mouse model
by: William Lee, et al.
Published: (2013-10-01)

Gene expression profiling of R6/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington's disease
by: Bin Tang, et al.
Published: (2011-06-01)

The contribution of glial cells to Huntington's disease pathogenesis
by: Daniel K. Wilton, et al.
Published: (2020-09-01)

Striatal Network Models of Huntington's Disease Dysfunction Phenotypes
by: Pengsheng Zheng, et al.
Published: (2017-07-01)

Striatal Vulnerability in Huntington’s Disease: Neuroprotection Versus Neurotoxicity
by: Ryoma Morigaki, et al.
Published: (2017-06-01)

Minocycline in phenotypic models of Huntington's disease
by: Kadiombo Bantubungi, et al.
Published: (2005-02-01)

A Study of Striatal Markers as Disease Modifiers in Huntington's Disease
by: Francelle, Laetitia
Published: (2014)

CAG repeat lengths ≥335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse
by: I. Dragatsis, et al.
Published: (2009-03-01)

Preserving cortico-striatal function: Deep brain stimulation in Huntington's disease
by: Sean J Nagel, et al.
Published: (2015-03-01)

Astrocytes from cortex and striatum show differential responses to mitochondrial toxin and BDNF: implications for protection of striatal neurons expressing mutant huntingtin
by: Julieta Saba, et al.
Published: (2020-10-01)

Functional roles for the striatal-enriched transcription factor, Bcl11b, in the control of striatal gene expression and transcriptional dysregulation in Huntington's disease
by: Paula A. Desplats, et al.
Published: (2008-09-01)

Fonction du récepteur nucléaire orphelin NR4A2 dans le contrôle de la neurogenèse chez Danio rerio
by: Blin, Maryline
Published: (2011)

Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease
by: Antonella Ferrante, et al.
Published: (2014-11-01)

Cannot write session to /tmp/vufind_sessions/sess_8j1c5ok45q2o110evjqaa7qj5a